Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Update

Virios Therapeutics, Inc. (NASDAQ:VIRI) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 579,800 shares, a decline of 33.9% from the July 15th total of 877,700 shares. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is presently 0.4 days.

Analyst Ratings Changes

Several brokerages have recently commented on VIRI. HC Wainwright reduced their target price on Virios Therapeutics from $0.40 to $0.20 and set a “neutral” rating for the company in a report on Friday, August 9th. Maxim Group started coverage on shares of Virios Therapeutics in a research note on Thursday, June 20th. They set a “buy” rating and a $1.00 price objective for the company.

Virios Therapeutics Price Performance

Virios Therapeutics stock traded up $0.01 during midday trading on Thursday, reaching $0.19. The stock had a trading volume of 171,175 shares, compared to its average volume of 851,374. Virios Therapeutics has a twelve month low of $0.16 and a twelve month high of $1.37. The firm has a market cap of $3.64 million, a price-to-earnings ratio of -0.65 and a beta of 1.61. The firm’s fifty day simple moving average is $0.23 and its two-hundred day simple moving average is $0.33.

Virios Therapeutics (NASDAQ:VIRI) last released its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. During the same period in the previous year, the business posted ($0.08) earnings per share. As a group, sell-side analysts predict that Virios Therapeutics will post -0.27 EPS for the current fiscal year.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.